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A B S T R A C T
Psoriasis is a chronic inflammatory skin disease that speeds up the life cycle of skin cells, forming scales and red patches that are itchy and sometimes painful. It is a
complex disease of autoimmune origin and genetic predisposition with more than 10 different loci associated. Here we described the production of an iPSC line
generated by Sendai Virus (Klf4, Oct3/4, Sox2 and c-Myc) reprogramming of Peripheral Blood Mononuclear Cells (PBMCs) from a Psoriasis patient. The iPSC line
generated has normal 46XY karyotype, is free of SeV genome and transgenes insertions, express high levels of pluripotency markers and can differentiate into all
three germ layers.
1. Resource Table
Unique stem cell line ide-
ntifier
IMEDEAi007-A
Alternative name(s) of st-
em cell line
hiPS IMEDEA-PBMCs CL1.12
Institution IMEDEA - Instituto Mediterráneo de Estudios Avanzados
Contact information of di-
stributor
Daniel Bachiller; d.b@csic.es
Type of cell line iPSCs
Origin Human
Additional origin info Age: 35 years
Sex: Male
Ethnicity if known: Caucasian
Cell Source Original cell type: Peripheral Blood Mononuclear Cell
Clonality Clonal cell line
Method of reprogramming CytoTune™-iPS 2.0 Sendai Reprogramming Kit
Genetic Modification NO
Type of Modification N/A
Associated disease Psoriasis 1, Susceptibility to PSORS1
(OMIM entry #177900)
Gene/locus N/A
Method of modification N/A






Date archived/stock date 9th June 2020
Cell line repository/bank Registered in the Human Pluripotent Stem Cell Registry
(https://hpscreg.eu)
Ethical approval Patient informed consent obtained/Comité Ético de
Investigación Clínica de las Islas Baleares (Spain)
Approval number IB3422/17PI
2. Resource utility
Although some treatments have shown disease remission, psoriasis
is still incurable. Due to the absence of psoriasis specific biomarkers and
the lack of a reliable animal model, iPSC could be used to build 3D
personalized psoriatic skin constructs, which in combination with mi-
crofluidic platforms, will contribute to a better understanding of the
diseases as well as to speed up drug development.
3. Resource details
Psoriasis is a complex chronic immune-mediated inflammatory skin
disease that affects 2–3% of the population and which cause is still not
fully understood. It is characterized by a dysregulation of im-
munological cell functions that trigger inflammatory reactions invol-
ving T-helper cells, dendritic cells and macrophages which, in turn,
induce the hyperproliferation of keratinocytes by the secretion of dif-
ferent cytokines. The lack of suitable pre-clinical models mimicking the
complex phenotype of the disease constitutes the main obstacle to study
the pathogenesis of psoriasis and to develop new therapies. In the last
decade, there has been a strong investment in the development of an in
vitro 3D skin models (Niehues and van den Bogaard, 2018) that offer the
opportunity to assess the contribution of different factors to the ae-
tiology of the disease. In this context, the use of psoriatic fibroblast/
keratinocytes in skin equivalents has demonstrate to partially preserve
their psoriatic characteristics (Desmet et al., 2017), however the scar-
city, limited size and heterogeneity of psoriasis skin biopsies and
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Fig.1. Characterization of a novel Psoriasis iPSC line IMEDEAi007-A. (A) Phase contrast image of the iPSC line growing on passage 19 on a feeder-coated plate
(scale bar = 100 μm). (B) Normal male karyotype of IMEDEAi007-A after G band analysis. (C) The expression of SOX2, OCT3/4, TRA 1-60 and NANOG in the iPSC
assessed by demonstrating absence of SeV genome and transgenes in 3 different passages of IMEDEAi007-A. (F) GAPDH, housekeeping control for PCR analysis. (G)
After 10 days of directed differentiation of the iPSCs into all three germ layers: ectoderm, mesoderm and endoderm, the expression of specific markers of each one of
the germ layers was tested by immunofluorescence assay.
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diagnosis makes this approach difficult to be developed by different
research groups. By using psoriasis-derived iPSCs lines, like IM-
EDEAi007-A, in the production of fibroblast and keratinocytes, it
should be possible to increase the reproducibility of the results obtained
at different times and places and therefore accelerate the study of this
disease and the development of possible treatments.
In order to avoid possible complications arising from inherent dif-
ferences in the biology of psoriasis-derived fibroblasts, the reprogram-
ming process was carried out with a pro-erythroblast enriched PBMCs
population from a 35 years old donor (diagnosed by histopathological
analysis of a skin biopsy specimen). Cells were reprogrammed using the
CytoTune 2.0 Sendai Reprogramming Kit carrying the 4 Yamanaka
factors (Klf4, Oct3/4, Sox2 and c-Myc). The IMEDEAi007-A cell line
generated showed a growth rate, behaviour and morphology (Fig. 1A)
typical of human Embryonic Stem Cells (hESC), as well as a normal
male genotype (46XY) (Fig. 1B). In addition, the iPSC line demon-
strated to be free of the SeV genome and transgenes integrations
(Fig. 1E and F) at three different cell passages (11, 18 and 30). Re-
garding the stemness of the line, immunocytochemical analysis showed
the expression of the pluripotency-associated markers: SOX2, OCT3/4,
TRA 1-60 and NANOG (Fig. 1C), and a specific and high TRA 1-81 and
SSEA-4 expression was confirmed by quantitative flow cytometry
(Fig. 1D). Finally, in order to probe the differentiation potential of the
iPSC line, directed differentiation into all three germ layers was carried
out (Fig. 1G). The expression of specific markers for ectoderm, meso-
derm and endoderm in the differentiated cells was analyzed by im-
munocytochemistry. Short tandem repeat (STR) analysis (Table 1, data
not shown) indicated a 100% match with parental PBMCs. The full
characterization of the line was completed determining the absence of
mycoplasma in iPSC samples (Supplementary Fig. S1).
To summarize, the iPSC generated from a Psoriasis donor has a great
potential for the study of the disease, as well as a screening tool in drug
development.
4. Materials and methods
4.1. iPSCs derivation and expansion
PBMCs were isolated by ficoll from a Psoriasis donor peripheral
blood sample. In order to select and expand a cell population without
rearrangements, PBMCs were cultured in a pro-erythroblast serum-free
specific media (1:1 IMDM/Ham’s F12 supplemented with: 1% ITS-X,
1% Chemically Defined Lipid Concentrate, 1% Glutamax, 0.025 g/L L-
Ascorbic Acid, 5 g/L BSA, 100 ng/ml SCF, 10 ng/ml IL3, 2U/ml EPO,
40 ng/ml IGF-1, 1 µM Dexamethasone and 100 µg/ml Holo-transferrin).
After 7 days of culture, 3 × 105 cells were transduced with CytoTune
2.0 Sendai Virus Reprogramming Kit (Invitrogen), using a MOI 5:5:3
(KOS:hc-Myc:hKlf4) and following the manufacturer recommendations.
After 3 days, 3 × 104 transduced cells/well were seed on a p6 well
MEF-CD1-coated plate. Pro-erythroblast culture medium was main-
tained for 4 more days, and then it was gradually changed to hiPS
medium until colonies were ready to be manually isolated 15 days after
reprogramming.
iPS colonies were grown on MEF CD1 until passage 3 when cells
where change to human Hafi-W3R feeders. Rock Inhibitor Y-27632 was
used at 10 μM during the passages to increase cell survival. Cells were
cultured at 37 °C and 5% CO2 in a humidified incubator.
4.2. Karyotype analysis
iPSCs were passed to Matrigel-coated plates and sent to Biobanco del
Sistema Sanitario Público de Andalucía (Granada, Spain) for the kar-
yotyping by G-banded metaphases analysis.
4.3. SeV genome and transgenes analysis
Genomic RNA was isolated (RNeasy Mini Kit, Qiagen) from iPSCs on
passage 11, 18 and 30 and from a pool of iPSCs 17 days after repro-
gramming as a positive control. After reverse transcription of RNA
(High Capacity cDNA Reverse Transcription Kit, AppliedBiosystems),
the presence of SeV genome and transgenes in hiPS cells was analysed
by PCR using the primers detailed in Table 2 and the WonderTaq
polymerase (Euroclone) for cDNA amplification.
4.4. STR analysis
STR analysis was performed by the Genomics Core facility at the
Instituto de Investigaciones Biomédicas (IIBM, Madrid).
4.5. In vitro directed differentiation
In order to perform directed differentiation of IMEDEAi007-A, iPSCs
were first cultured on gelatin-coated plates in hiPS medium supple-
mented with 10 μM Rock Inhibitor and 1% of DMSO. After 75 min cells
Table 1
Characterization and validation.
Classification Test Result Data
Morphology Photography Normal appearance of packed iPS colonies. Scale bars: 100 μm Fig. 1 panel A
Phenotype Qualitative analysis by
Immunocytochemistry
The cell line expressed the pluripotency markers: SOX2, OCT3/4, TRA-1-60
and NANOG.
Fig. 1 panel C
Quantitative analysis by Flow
Cytometry
The cell line expressed high levels of the pluripotency markers SSEA-4 and
TRA-1–81
Fig. 1. Panel D
Genotype Karyotype (G-banding) and resolution IMEDEAi007-A: 46, XY
Resolution 450–500
Fig. 1. Panel B
Identity Microsatellite PCR analysis
STR analysis
Not performed








Microbiology and virology Mycoplasma Mycoplasma testing by PCR using MycoSPY Kit (Biontex). Submitted in archive
with journal
Differentiation potential Directed differentiation The cell line differentiated into the three germ layers including ectoderm
(Nestin, Pax6 and TUJ-1), mesoderm (GATA-4, α-SMA and Vimentin) and
endoderm (Sox17, AFP and FoxA2).
Fig. 1. Panel G
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were passed to a p48 well plate coated with matrigel. Ectoderm dif-
ferentiation was carried out according to Tchieu et al. (2017), but using
200 ng/ml Noggin (Peprotech) instead of LDN193189. Mesoderm dif-
ferentiation was attained following Oldershaw et al. (2008), while the
protocol of McCracken et al. (2011) was applied, with some minor
modifications, for endoderm differentiation. After 10 days of culture
cells were fixed in PFA 4% for immunocytochemistry.
4.6. Immunofluorescence staining
Undifferentiated iPSCs (for pluripotency markers assays) and dif-
ferentiated cells (for differentiation potential assays) were washed with
PBS, fixed for 20 min, washed again with PBS and permeabilized with
0.2% Triton X-100 and 100 mM glycine in PBS for 30 min at room
temperature (RT). To block non-specific binding sites, PBS 5% BSA was
added an incubated for 60 min at RT. Primary antibodies incubation
was done overnight at 4 °C in PBS 2% BSA. After three washes with PBS,
cells were incubated with fluorescence-conjugated secondary anti-
bodies in PBS 2% BSA for 60 min at RT and darkness. The antibodies
used are described in Table 2. After washing with PBS, cells were
stained with DAPI for 5 min at RT in darkness.
4.7. Flow cytometry analysis of pluripotency marker
Cells were detached with Tryple and incubated 45 min and 4 °C with
conjugated antibodies (Table 2) against cells surface markers TRA-1-81
and SSEA-4. The corresponding isotype antibodies were used as con-
trols. Influx Cell Sorter and BD 1.0.0.650 Software were used for the
cytometry analysis.
4.8. Mycoplasma detection
Mycoplasma testing was carried out using the MycoSPY
Mycoplasma PCR detection kit (Biontex), which detects a wide range of
bacteria from the Mollicutes class. An Internal Control template was
included to discard the presence of PCR inhibitors and rule out false
positive results.
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Table 2
Reagent details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID








Santa Cruz Biotech; sc-5279; RRID:AB_628051
Cell Signaling; D73G4; RRID:AB_10559205
R and D Systems; MAB2018; RRID:AB_177629
Millipore; MAB4360; RRID:AB_2119183






























Secondary antibodies Alexa Fluor 555 Donkey Anti-Rabbit IgG
Alexa Fluor 555 Donkey Anti-Mouse IgG
Alexa Fluor 488 Donkey Anti-Mouse IgG
Alexa Fluor 555 Donkey Anti-Goat IgG










Invitrogen; A-21432, RRID: AB_2535853
Invitrogen; A-21206
RRID:AB_141708
Antibodies used for Flow Cytometry
Antibody Vol. per test Company Cat # and RRID
Pluripotency Markers Mouse Anti TRA-1–81, APC
Mouse Anti SSEA-4, PE
Mouse IgM, k Isotype Control, APC





BD Biosciences; 560793; RRID:AB_10550550
BD Biosciences; 560,128
RRID:AB_1645533




Target Forward/Reverse primer (5′-3′)












House-Keeping Genes (PCR) GAPDH GCACCGTCAAGGCTGAGAAC/ AGGGATCTCGCTCCTGGAA
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